[Skip to Content]
[Skip to Content Landing]
March 10, 1997

The PDR: Another View

Author Affiliations

Blytheville, Ark

Arch Intern Med. 1997;157(5):576. doi:10.1001/archinte.1997.00440260144021

Two concerns came to mind as I read "The Physicians' Desk Reference [PDR]: Problems and Possible Improvements" by Cohen and Insel.1 The PDR2 must be viewed as a form of advertising (in a reference format) in which pharmaceutical manufacturers present information on medications that they pick and choose by presenting package insert information approved by the Food and Drug Administration (FDA).

As Cohen and Insel aptly noted, the information presented is reviewed and approved by the FDA. The PDR should not be viewed as anything more than a collection of advertising in a reference format. I have always found the PDR to be invaluable when I need to identify a medication or review the FDA-approved prescribing information. I would not want to see an effort made to allow the pharmaceutical companies to provide additional information of their own choosing in a compilation such as the PDR unless the

First Page Preview View Large
First page PDF preview
First page PDF preview